Molecular Partners AG (MOLN)
3.87
+0.16
(+4.31%)
USD |
NASDAQ |
May 16, 16:00
Molecular Partners Research and Development Expense (Quarterly): 14.50M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 14.50M |
| September 30, 2023 | 13.14M |
| June 30, 2023 | 12.94M |
| March 31, 2023 | 13.71M |
| December 31, 2022 | 12.69M |
| September 30, 2022 | 11.90M |
| June 30, 2022 | 13.03M |
| Date | Value |
|---|---|
| March 31, 2022 | 15.67M |
| December 31, 2021 | 13.51M |
| September 30, 2021 | 12.72M |
| June 30, 2021 | 16.93M |
| March 31, 2021 | 17.87M |
| December 31, 2020 | 20.10M |
| September 30, 2020 | 13.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
11.90M
Minimum
Sep 2022
20.10M
Maximum
Dec 2020
14.47M
Average
13.61M
Median
Research and Development Expense (Quarterly) Benchmarks
| AC Immune SA | 17.35M |
| CRISPR Therapeutics AG | 76.17M |
| Addex Therapeutics Ltd | 0.5126M |
| NLS Pharmaceutics Ltd | -- |
| MoonLake Immunotherapeutics | 13.01M |